Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enact Holdings Inc (ACT) vs Eli Lilly And Co (LLY) Price & Performance

Enact Holdings IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Enact Holdings Inc vs Eli Lilly And Co — how do they compare? Enact Holdings Inc trades at $49.07 (market cap $6.67B), while Eli Lilly And Co trades at $1,215.09 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 164.9× Enact Holdings Inc's market cap, and Enact Holdings Inc pays the higher dividend (1.98%). Which is the better fit depends on your goals.

ACTLLY
Market Cap
$6.67B$1.10T
Sector
TechnologyHealth
52-Week High
$49.12$1.24K
52-Week Low
$34.93$639.43
Enterprise Value
$6.96B$1.14T
Dividend Yield
1.98%0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enact Holdings Inc

ACT trades at $48.96, up 0.6% today, near the consensus price target of $49.00. The stock shows strong fundamentals with a P/E of 10.23 and robust net income margin of 54.51%. Recent Q2 2026 earnings beat expectations at $1.26 per share. Technical indicators signal a bullish trend with moving averages supporting upside momentum. The company maintains consistent dividend payments and positive revenue growth projections.

Outlook remains positive with analyst consensus favoring buy/hold ratings and price targets suggesting limited upside. Key risks include execution challenges and market volatility. Earnings growth and dividend consistency provide support, but investors should monitor competitive pressures and macroeconomic factors that could impact performance.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enact Holdings Inc

Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.

Read more on ACT

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY